title: Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?
authors.forename: Virginia G
authors.initials: VG
authors.lastname: Kaklamani
authors.forename: William J
authors.initials: WJ
authors.lastname: Gradishar
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D011300:Preoperative Care; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C485206:pertuzumab